385 related articles for article (PubMed ID: 27184486)
1. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
El-Ghammaz AM; Abdelwahed E
Ann Hematol; 2016 Aug; 95(8):1315-21. PubMed ID: 27184486
[TBL] [Abstract][Full Text] [Related]
2. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
Avet-Loiseau H; Leleu X; Roussel M; Moreau P; Guerin-Charbonnel C; Caillot D; Marit G; Benboubker L; Voillat L; Mathiot C; Kolb B; Macro M; Campion L; Wetterwald M; Stoppa AM; Hulin C; Facon T; Attal M; Minvielle S; Harousseau JL
J Clin Oncol; 2010 Oct; 28(30):4630-4. PubMed ID: 20644101
[TBL] [Abstract][Full Text] [Related]
4. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.
Kaufman GP; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Dingli D; Hayman SR; Kapoor P; Lust JA; Russell S; Go RS; Hwa YL; Kyle RA; Rajkumar SV; Kumar SK
Leukemia; 2016 Mar; 30(3):633-9. PubMed ID: 26487275
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial.
Ho PJ; Brown RD; Spencer A; Jeffels M; Daniher D; Gibson J; Joshua DE
Leuk Lymphoma; 2012 Sep; 53(9):1728-34. PubMed ID: 22329352
[TBL] [Abstract][Full Text] [Related]
8. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Neben K; Lokhorst HM; Jauch A; Bertsch U; Hielscher T; van der Holt B; Salwender H; Blau IW; Weisel K; Pfreundschuh M; Scheid C; Dührsen U; Lindemann W; Schmidt-Wolf IG; Peter N; Teschendorf C; Martin H; Haenel M; Derigs HG; Raab MS; Ho AD; van de Velde H; Hose D; Sonneveld P; Goldschmidt H
Blood; 2012 Jan; 119(4):940-8. PubMed ID: 22160383
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
[TBL] [Abstract][Full Text] [Related]
10. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
11. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
[TBL] [Abstract][Full Text] [Related]
12. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.
Chakraborty R; Muchtar E; Kumar S; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Bone Marrow Transplant; 2017 Jan; 52(1):34-40. PubMed ID: 27548464
[TBL] [Abstract][Full Text] [Related]
13. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.
Leleu X; Karlin L; Macro M; Hulin C; Garderet L; Roussel M; Arnulf B; Pegourie B; Kolb B; Stoppa AM; Brechiniac S; Marit G; Thielemans B; Onraed B; Mathiot C; Banos A; Lacotte L; Tiab M; Dib M; Fuzibet JG; Petillon MO; Rodon P; Wetterwald M; Royer B; Legros L; Benboubker L; Decaux O; Escoffre-Barbe M; Caillot D; Fermand JP; Moreau P; Attal M; Avet-Loiseau H; Facon T;
Blood; 2015 Feb; 125(9):1411-7. PubMed ID: 25575538
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
15. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Einsele H; Engelhardt M; Tapprich C; Müller J; Liebisch P; Langer C; Kropff M; Mügge LO; Jung W; Wolf HH; Metzner B; Hart C; Gramatzki M; Hertenstein B; Pfreundschuh M; Rösler W; Fischer T; Maschmeyer G; Kanz L; Hess G; Jäger E; Bentz M; Dürk HA; Salwender H; Hebart H; Straka C; Knop S
Br J Haematol; 2017 Nov; 179(4):586-597. PubMed ID: 28961309
[TBL] [Abstract][Full Text] [Related]
16. Induction therapy in multiple myeloma.
Harousseau JL
Hematology Am Soc Hematol Educ Program; 2008; ():306-12. PubMed ID: 19074101
[TBL] [Abstract][Full Text] [Related]
17. Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion.
Kitamura H; Kubota Y; Yamaguchi K; Kamachi K; Nishioka A; Yokoo M; Shindo T; Ando T; Kojima K; Kimura S
Intern Med; 2018 Mar; 57(6):855-860. PubMed ID: 29151530
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
19. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
[TBL] [Abstract][Full Text] [Related]
20. 17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management.
Lee J; Smith D; Rabin N; Tobias J; Yong K
Hematol Oncol; 2016 Sep; 34(3):165-70. PubMed ID: 26073569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
